INmune Bio, Inc. INMB 深 沪
等待开盘 03-26 09:30:00 美东时间
1.22
+0.040
+3.39%
华盛通- 最 高1.24
- 今 开1.19
- 成交量 23.20万股
- 最 低 1.18
- 昨 收 1.18
- 总市值 3243.40万
- 52周最高 11.64
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 1.15
- 委 比 90.15%
- 总股本 2658.53万
- 历史最高 30.37
- 量 比 0.29
- 振 幅 5.08%
- 历史最低 1.15
- 每 手 1
- 风险率 2.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多INmune Bio To Feature Phase 2 MINDFuL Trial Of XPro As Centerpiece Of Plenary Presentation At AD/PD 2026
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer's Drug DevelopmentBoca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) --
03-19 21:28
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
Malú Gámez Tansey, Ph.D., will present INmune Bio’s Phase 2 MINDFuL trial of XPro™ at AD/PD 2026, highlighting the company’s biomarker enrichment strategy for targeting Alzheimer’s patients with peripheral inflammation. XPro™, a soluble TNF inhibitor, demonstrated strong efficacy in inflamed patient subgroup. INmune Bio is advancing a Phase 2b/3 program for XPro1595 in early Alzheimer’s patients, supported by FDA alignment and promising clinical ...
03-19 12:00
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
LUCID CAPITAL MARKETS Upgrades INmune Bio to Buy, Raises Price Target to $9
LUCID CAPITAL MARKETS analyst Elemer Piros upgrades INmune Bio (NASDAQ:INMB) from Neutral to Buy and raises the price target from $2 to $9.
03-11 20:01
INmune Bio to Present New CORDStrom Phase III Data
The latest update is out from Inmune Bio ( ($INMB) ). On February 19, 2026, INm...
02-20 05:58
INmune Bio to Host Webinar Presenting New CORDStrom Clinical Data for RDEB
INmune Bio to Host Webinar Presenting New CORDStrom Clinical Data for RDEB INmune Bio Inc. will host a webinar on CORDStrom™ for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on Feb. 26, 2026 at 1:00 p.m. ET, featuring new clinical data from the MissionEB Phase III study and ins
02-20 01:15
INmune Bio Advances XPro1595 to Phase 2b/3 Trial in Early Alzheimer’s Disease
INmune Bio Advances XPro1595 to Phase 2b/3 Trial in Early Alzheimer’s Disease INmune Bio Inc. announced that it has received official feedback from the U.S. Food and Drug Administration (FDA) confirming regulatory alignment on the company’s proposed integrated Phase 2b/3 clinical development strateg
02-12 20:00
